Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06290128 | A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work | PHASE3 | RECRUITING | 140 | — | — | Jul 12, 2024 | Nov 20, 2028 | May 26, 2026 | 128 | United States, Argentina +22 |
A response is defined as a decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24.
Lasting response is defined as a decrease of ≥1 point in adjusted INCAT disability score at week 48 versus baseline.
A response is defined as a decrease of ≥1 point in adjusted INCAT disability score at Week 48 versus week 24.
| Arm | Type | Description |
|---|---|---|
| Riliprubart Arm | EXPERIMENTAL | Riliprubart for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks |
| Placebo Arm | PLACEBO_COMPARATOR | Placebo for 24 weeks followed by open-label extension phase with riliprubart for 24 weeks |
| Name | Type | Description |
|---|---|---|
| Riliprubart | DRUG | Pharmaceutical form: Solution Route of administration: IV Infusion |
| Placebo | DRUG | Pharmaceutical form: Solution Route of administration: IV Infusion |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Participant must have CIDP or possible CIDP criteria, based on European Academy of Neurology (EAN)/ Peripheral Nerve Society (PNS) Task Force CIDP guidelines, second revision (2...